Supplemental Figure 2: Baseline T-cell subsets as a percentage of CD45+ T cells. Significance testing of early-stage against metastatic TNBC cohorts is by t-test. Significance testing within early and metastatic cohorts is by the Kruskal-Wallis method. HR+, hormone receptor positive; HER2-neu negative; HER2+, HER2-neu positive; eTNBC, early stage TNBC; Naive, chemotherapy-naive; >12 mo, >12 months since last chemotherapy; 6-12 mo, 6-12 months since last chemotherapy; Treg, regulatory T cell; CM, central memory; EM, effector memory; EMRA, effector memory cells re-expressing CD45RA.